Special Lecture | Sodium Channel Blocking Antiseizure Medications & The Heart: Sifting and Winnowing the Data
Friday, December 3, 2021
-
You may need to log in to view video on this page.
OVERVIEW
Earlier this year, the US Food and Drug Administration (FDA) added warnings regarding cardiac rhythm and conduction abnormalities to the label for lamotrigine.
This session alerts epilepsy providers about the new FDA safety concerns for lamotrigine and other sodium channel blocking ASMs, and offers guidance for clinical care and communicating with patients. Faculty share their expertise in basic pharmacology, cardiology, and epilepsy clinical care in the context of new warnings not only regarding lamotrigine, but potential concerns with other commonly used ASMs in this general class. This inter-professional panel addresses potential risks and risk mitigation from a cardiologist and neurologist perspective.
Learning Objectives:
Following participation in this activity, participants will be able to:
- Describe the recent FDA warnings on use of lamotrigine in patients with cardiac conditions
- Identify the ion channels that comprise the cardiac electrical activation recovery process and the impact that Na+ channel blocking and QT prolonging drugs have on the risk of cardiac arrhythmias
- Recognize which patients should receive an EKG or cardiology consult is association with use of ASMs, in order to minimize risk
- Share clinical perspectives related to clinical challenges and to communicating with patients about the potential cardiac risk associated with ASM therapy
Program:
Chairs: Barry E. Gidal, PharmD and David G. Vossler, MD, FAES
Introduction | Barry E. Gidal, PharmD, FAES
In Vitro Assessments of the Cardiac Safety of Sodium Channel ASMs | David S. Auerbach, PhD, FAES
Sodium Channel Blockade: Friend or Foe? | Lennart Bergfeldt, MD, PhD
Clinical Perspective: What do We Need from our Regulators? | David G. Vossler, MD, FAES
Clinical Perspective: How Should the Clinician Proceed? | Jacqueline A. French, MD, FAES
Panel Discussion | All Faculty
Education Credit:
2.0 CME